| Ouverture: | - |
| Variation: | - |
| Volume: | - |
| + Bas: | - |
| + Haut: | - |
| Ecart + Bas / + Haut: | - |
| Type: | Actions |
| Ticker: | ALMDT |
| ISIN: | FR0011049824 |
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of April 30, 2025
- 66
Regulatory News:
Median Technologies (Paris:ALMDT):
Total number of shares |
19,129,120 |
Number of real voting rights* (excluding treasury shares**) |
19,065,961 |
Theoretical number of voting rights* (including treasury shares**) |
19,105,920 |
(*) Class E preference shares are non-voting |
|
(**) pursuant to article 223-11 of the AMF’s General Regulations |
|
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250516352933/en/
